Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 double-blind, randomized, placebo-controlled trial of Omilancor in patients with mild-to-moderately active Ulcerative Colitis

Next Previous
Search
Trial Profile

Phase 3 double-blind, randomized, placebo-controlled trial of Omilancor in patients with mild-to-moderately active Ulcerative Colitis

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omilancor (Primary)
  • Indications Ulcerative colitis
  • Focus Registrational; Therapeutic Use
  • Acronyms PACIFY II
  • Sponsors Landos Biopharma

    • Most Recent Events

    • 11 Apr 2025 According to NImmune Biopharma media release, company will present results from this trial at Digestive Disease Week 2025. DDW 2025 will be held at the San Diego Convention Center from May 3-6, 2025.
    • 17 May 2023 According to NImmune Biopharma media release, company expects to dose the first patient in the global pivotal Phase 3 PACIFY program by years end.
    • 17 May 2023 According to NImmune Biopharma media release, PACIFY is a global registration directed double-blind randomized placebo-controlled Phase 3 program of omilancor in active UC patients ranging from mild to severe that aims to enroll 1,378 patients across 250 global clinical sites

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top